GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

pozelimab   Click here for help

GtoPdb Ligand ID: 12900

Synonyms: pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
Approved drug Immunopharmacology Ligand
pozelimab is an approved drug (FDA (2023))
Compound class: Antibody
Comment: Pozelimab (REGN-3918) targets the terminal complement component C5 [1]. It is designed to inhibit complement pathway activation and complement-mediated inflammatory tissue damage.
Classification Click here for help
Compound class Antibody
Approved drug? Yes. US FDA (2023)
International Nonproprietary Names Click here for help
INN number INN
10945 pozelimab
Synonyms Click here for help
pozelimab-bbfg | REGN-3918 | REGN3918 | Veopoz®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 898
Other databases
GtoPdb PubChem SID 485206021
Search PubMed clinical trials pozelimab
Search PubMed titles pozelimab
Search PubMed titles/abstracts pozelimab